L 163255

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596401

CAS#: 159634-54-5

Description: L 163255 is a growth hormone secretagogue (GHS).


Price and Availability

Size
Price

Size
Price

Size
Price

L 163255 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 596401
Name: L 163255
CAS#: 159634-54-5
Chemical Formula: C28H39ClN4O4S
Exact Mass:
Molecular Weight: 563.15
Elemental Analysis: C, 59.72; H, 6.98; Cl, 6.29; N, 9.95; O, 11.36; S, 5.69


Synonym: L 163255; L-163,255; L 163,255; L163,255; L-163255; L163255;

IUPAC/Chemical Name: 2-amino-2-methyl-N-(1-(1-(methylsulfonyl)spiro[indoline-3,4'-piperidin]-2-yl)-1-oxo-5-phenylpentan-2-yl)propanamide hydrochloride

InChi Key: ZFNCYAUKHUSCBF-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H38N4O4S.ClH/c1-27(2,29)26(34)31-22(14-9-12-20-10-5-4-6-11-20)24(33)25-28(16-18-30-19-17-28)21-13-7-8-15-23(21)32(25)37(3,35)36;/h4-8,10-11,13,15,22,25,30H,9,12,14,16-19,29H2,1-3H3,(H,31,34);1H

SMILES Code: CC(C)(N)C(NC(C(C1N(S(=O)(C)=O)C2=C(C=CC=C2)C13CCNCC3)=O)CCCC4=CC=CC=C4)=O.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Liantonio A, Gramegna G, Carbonara G, Sblendorio VT, Pierno S, Fraysse B, Giannuzzi V, Rizzi L, Torsello A, Camerino DC. Growth hormone secretagogues exert differential effects on skeletal muscle calcium homeostasis in male rats depending on the peptidyl/nonpeptidyl structure. Endocrinology. 2013 Oct;154(10):3764-75. doi: 10.1210/en.2013-1334. Epub 2013 Jul 8. PubMed PMID: 23836033.

2: Luque RM, Peinado JR, Gracia-Navarro F, Broglio F, Ghigo E, Kineman RD, Malagón MM, Castaño JP. Cortistatin mimics somatostatin by inducing a dual, dose-dependent stimulatory and inhibitory effect on growth hormone secretion in somatotropes. J Mol Endocrinol. 2006 Jun;36(3):547-56. PubMed PMID: 16720722.

3: Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005 May;26(3):346-60. Epub 2005 Apr 6. Review. PubMed PMID: 15814848.

4: Thompson NM, Gill DA, Davies R, Loveridge N, Houston PA, Robinson IC, Wells T. Ghrelin and des-octanoyl ghrelin promote adipogenesis directly in vivo by a mechanism independent of the type 1a growth hormone secretagogue receptor. Endocrinology. 2004 Jan;145(1):234-42. Epub 2003 Oct 9. PubMed PMID: 14551228.

5: Krieg RJ Jr, Chan W, Lin KC, Kuemmerle NB, Veldhuis JD, Chan JC. Growth hormone and growth hormone-related mRNA in uremic rats: effect of a growth hormone secretagogue. Pediatr Nephrol. 2002 Aug;17(8):585-90. Epub 2002 Jun 7. PubMed PMID: 12185462.

6: Moulas AN, Krieg RJ Jr, Veldhuis JD, Chan JC. Effect of the GH secretagogue L-163,255 and restricted feeding time on GH pulsatility in the rat. Eur J Endocrinol. 2002 Jul;147(1):143-8. PubMed PMID: 12088931.

7: Gracia-Navarro F, Castaño JP, Malagon MM, Sánchez-Hormigo A, Luque RM, Hickey GJ, Peinado JR, Delgado E, Martínez-Fuentes AJ. Research progress in the stimulatory inputs regulating growth hormone (GH) secretion. Comp Biochem Physiol B Biochem Mol Biol. 2002 May;132(1):141-50. Review. PubMed PMID: 11997217.

8: Geris KL, Hickey GJ, Vanderghote A, Kühn ER, Darras VM. Synthetic growth hormone secretagogues control growth hormone secretion in the chicken at pituitary and hypothalamic levels. Endocrine. 2001 Feb;14(1):67-72. PubMed PMID: 11322503.

9: Drisko JE, Faidley TD, Zhang D, McDonald TJ, Nicolich S, Hora DF, Cunningham P, Li C, Rickes E, McNamara L, Chang C, Smith RG, Hickey GJ. Administration of a nonpeptidyl growth hormone secretagogue, L-163, 255, changes somatostatin pattern, but has no effect on patterns of growth hormone-releasing factor in the hypophyseal-portal circulation of the conscious pig. Proc Soc Exp Biol Med. 1999 Oct;222(1):70-7. PubMed PMID: 10510248.

10: Christensen RA, Malinowski K, Scanes CG, Hafs HD. Pulsatile release of somatotropin related to meal feeding and somatotropin response to secretagogues in horses. J Anim Sci. 1997 Oct;75(10):2770-7. PubMed PMID: 9331883.

11: Lieber RL, Jacks TM, Mohler RL, Schleim K, Haven M, Cuizon D, Gershuni DH, Lopez MA, Hora D Jr, Nargund R, Feeney W, Hickey GJ. Growth hormone secretagogue increases muscle strength during remobilization after canine hindlimb immobilization. J Orthop Res. 1997 Jul;15(4):519-27. PubMed PMID: 9379261.

12: Chang CH, Rickes EL, McGuire L, Frazier E, Chen H, Barakat K, Nargund R, Patchett A, Smith RG, Hickey GJ. Growth hormone (GH) and insulin-like growth factor I responses after treatments with an orally active GH secretagogue L-163,255 in swine. Endocrinology. 1996 Nov;137(11):4851-6. PubMed PMID: 8895356.